Our results in the zymographic assays for gelatinase and urokinase activities clearly showed that, in fact, kahweol was able to inhibit the expression of both MMP - 2 and uPA, identifying them as two relevant molecular targets
for kahweol.
This effect on cell survival was not endothelial cell - specific, since IC50 values
for kahweol treatment of several human tumoral cell lines were similar to those obtained for HUVEC (results not shown).
The minimal inhibitory concentration
for kahweol in this assay of «tubule - like» structures formation on Matrigel was 25 µM, in the range of concentrations at which other known antiangiogenic compounds produce this kind of effect [13], [27].
Not exact matches
In contrast, Video S2 shows that larvae treated with 50 µM
kahweol for 24 h exhibited no blood flow along intersegmental vessels.
The global morphological features (including centrifugal growth of the peripheral vessels - relative to the position of the disc -, avoiding the treated area, with an overall decrease in the vascular density) elicited by
kahweol treatment are also in agreement with those previously observed
for other anti-angiogenic compounds.
Six eggs were used
for each tested dose of
kahweol.
Subconfluent HUVEC cultures were stimulated with PMA (50 ng / mL)
for 4 h in the absence (controls) or presence of different concentrations of
kahweol.
Conditioned media from untreated and
kahweol treated HUVEC cells
for 24 h were obtained.
All these effects may open a window
for the potential therapeutical application of
kahweol as an anti-angiogenic drug.
We show
for the first time that
kahweol is an anti-angiogenic compound with inhibitory effects in two in vivo and one ex vivo angiogenesis models, with effects on specific steps of the angiogenic process: endothelial cell proliferation, migration, invasion and tube formation on Matrigel.